title: Adoptive cellular therapy for chronic lymphocytic leukemia and B cell malignancies. CARs and more.
abstract: Treatment of patients with chronic lymphocytic leukemia and other B cell malignancies is evolving very rapidly. We have observed the quick transition during the last couple of years, from chemo-immunotherapy based treatments to oral targeted therapies based on B cell receptor signaling and Bcl-2 inhibitors, as well as the increasing use of second generation glyco-engineered antibodies. The next wave of revolution in the treatment for this conditions is approaching and it will be based on strategies that harness the power of the immune system to fight cancer. In the center of this biotechnological revolution is cellular engineering, the field that had made possible to redirect the immune system effector cells to achieve a more effective and targeted adoptive cellular therapy. In this chapter, we will review the historical context of these scientific developments, the most recent basic and clinical research in the field and some opinions regarding the future of adoptive cellular therapy in CLL and other B cell malignancies.
authors.affiliation: Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA, USA; CLL Research Consortium, USA. Electronic address: jecastro@ucsd.edu.
authors.forename: Januario E
authors.initials: JE
authors.lastname: Castro
authors.affiliation: Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA, USA; CLL Research Consortium, USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Kipps
mesh_terms: D019264:Adoptive Transfer; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000378:metabolism / Q000628:therapy*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors / Q000378:metabolism; D011947:Receptors, Antigen, B-Cell; D011993:Recombinant Fusion Proteins
chemical_list: C000595707:BCL2 protein, human; D019253:Proto-Oncogene Proteins c-bcl-2; D011947:Receptors, Antigen, B-Cell; D011993:Recombinant Fusion Proteins
keywords: Adoptive cellular therapy; B cell malignancy; CLL; Cellular engineering